Prophylactic Vaccine Strategies and the Potential of Therapeutic Vaccines Against Herpes Simplex Virus

Title: Prophylactic Vaccine Strategies and the Potential of Therapeutic Vaccines Against Herpes Simplex Virus

Volume: 13 Issue: 19

Author(s): Michael W. Ferenczy

Affiliation:

Keywords: HSV-1, therapeutic vaccine, cytokine adjuvant, DNA vaccine

Abstract: Herpes Simplex Virus Type 1 (HSV-1) infection is widespread and causes significant disease. A number of prophylactic vaccine strategies have elicited protective immunity in animal models, but no human vaccine has yet been effective. Asymptomatic HSV-1 infection is common, demonstrating that the immune system is able to control infection, despite failure to clear the virus. Therefore, therapeutic vaccination may be a viable strategy against HSV-1. This review will discuss the epidemiology, molecular biology, and immune response to HSV-1, prophylactic and therapeutic vaccine strategies, and the potential of future therapeutic HSV-1 vaccines to reduce or eliminate HSV-1 pathology.

Cite this article as:

Michael W. Ferenczy , Prophylactic Vaccine Strategies and the Potential of Therapeutic Vaccines Against Herpes Simplex Virus, Current Pharmaceutical Design 2007; 13 (19) . https://dx.doi.org/10.2174/138161207781039779